Yahoo Web Search

Search results

  1. People also ask

  2. Mar 13, 2023 · What is nifurtimox? Nifurtimox is used to treat Chagas disease, a condition caused by a parasite. Chagas disease occurs most commonly in Mexico, Central America, and South America. Nifurtimox is for use in children from birth through their 17th year. A child must weigh at least 5.5 pounds (2.5 kilograms) before taking nifurtimox.

  3. Nifurtimox is used to treat Chagas disease (an infection caused by a parasite) in children from birth to 18 years old who weigh at least 5.5 pounds (2.5 kg). Nifurtimox is in a class of medications called antiprotozoals. It works by killing the organism that can cause Chagas disease.

  4. Nifurtimox is used to treat a certain parasitic infection ( Chagas disease ). It works by stopping the growth of a certain parasite. How to use Nifurtimox 120 Mg Tablet. Read the...

  5. Sep 19, 2023 · Nifurtimox is a medication used to treat Chagas disease, also known as American trypanosomiasis, in pediatric patients. Nifurtimox is under investigation and not yet approved for the treatment of Chagas disease in adults. Nifurtimox is an antiprotozoal agent that kills Trypanosoma cruzi, the parasite that causes Chagas disease.

  6. en.wikipedia.org › wiki › NifurtimoxNifurtimox - Wikipedia

    Medical uses. Pregnancy and breastfeeding. Side effects. Contraindications. Mechanism of action. Society and culture. Legal status. Names. Research. References. External links. Nifurtimox, sold under the brand name Lampit, is a medication used to treat Chagas disease and sleeping sickness.

    • C₁₀H₁₃N₃O₅S
    • By mouth
    • Lampit
  7. Sep 19, 2023 · What Is Nifurtimox Used For and How Does it Work? Nifurtimox is an investigational drug used to treat American trypanosomiasis (Chagas disease). Nifurtimox is available under the following different brand names: Lampit.

  8. Oct 20, 2016 · Nifurtimox, developed by Bayer, is a nitrofuran antiprotozoal drug used in the treatment of Chagas disease. On August 6 2020, accelerated FDA approval was granted for its use in pediatric patients in response to promising results from phase III clinical trials.

  1. People also search for